# Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/gemcitabine-and-paclitaxel-every-2-weeks-in-patients-with-previously-untreated/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Fabio Calabrò,Vito Lorusso,Gerardo Rosati,Luigi Manzione,Luca Frassineti,Teodoro Sava,Eugenio Donato Di Paula,S. Alonso,Cora N. Sternberg |
| Citations | 92 |
| DOI | 10.1002/cncr.24313 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.24313 |
| OpenAlex ID | https://openalex.org/W2038587487 |
| PMID | 19396817 |
| Type | article |
| Year | 2009 |

## Paper authors

- [Gerardo Rosati](https://scholariq.org/researchers/gerardo-rosati/)

## Paper journal

- [Cancer](https://scholariq.org/journals/cancer/)

## Paper primary topic

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

## Paper topics

- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.